Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 701–800 of 991
Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren
Koelzer, V. H., Glatz, K., Bubendorf, L., Weber, A., Gaspert, A., Cathomas, G., Lugli, A., Zippelius, A., Kempf, W., & Mertz, K. D. (2017) · Der Pathologe · doi:10.1007/s00292-017-0281-1 · Cited by 7
Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
Ma, J., Wei, Q., Cheng, X. M., Zhang, J., Zhang, Z., & Su, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170591 · Cited by 9
Li, H., Guo, X., Liu, X., Zhao, J., Chen, W., & Yang, B. K. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105326 · Cited by 7
When old metagenomic data meet newly sequenced genomes, a case study
Li, X., Naser, S. A., Khaled, A. R., Hu, H., & Li, X. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198773 · Cited by 7
Microbiome transplantation and modulation of immune related adverse events
Smibert, O. C., Guo, C. W., Khoo, C. C. H., Thursky, K., Sandhu, S. K., & Slavin, M. A. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.03.003 · Cited by 9
“In humans, certain bacterial phyla have been linked with both resistance to and the development of irAE, particularly those involving the gastrointestinal tract [8, 9].”
BackgroundSanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2021) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2020.07.007 · Cited by 10
Alatawi, H. A., Mosli, M. H., Saadah, O. I., Dulai, P. S., Al-Hindi, R. R., Bahieldin, A., & Edris, S. (2020) · Applied Ecology and Environmental Research · doi:10.15666/aeer/1804_55055525 · Cited by 6
“It has also been postulated that some microbiota species possess the capacity to modify and improve the effects of therapy (Dubin et al., 2016; Routy et al., 2018).”
BackgroundNovel Biomarkers and Druggable Targets in Advanced Melanoma
Ferrucci, P. F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers14010081 · Cited by 8
Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
Hamada, K., Tsunoda, T., & Yoshimura, K. (2022) · Life · doi:10.3390/life12081229 · Cited by 8
Interaction of microbiome and immunity in tumorigenesis and clinical treatment
Yu, Y., & Zhong, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113894 · Cited by 10
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
Zhou, Y., & Ding, S. (2023) · Cancers · doi:10.3390/cancers15235622 · Cited by 7
“…patients [72] and low Bacteroidetes / Firmicutes ratios presented in NSCLC, SCLC, or uterine endometrial dediffer-entiated cancer patients with ICI-related acute pancreatitis [26], which is consistent with the discovery of protection of Bacteroidetes phylum from colitis in melanoma patients [73].”
ResultClinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
Mok, K. K. S., Wu, C., Chan, S. L., Wong, G. L., Wong, V. W., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.12.003 · Cited by 10
Gastrointestinal Tract Adverse Events
Abu‐Sbeih, H., & Wang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_12 · Cited by 9
Microbiota modification in hematology: still at the bench or ready for the bedside?
Severyn, C. J., Brewster, R., & Andermann, T. M. (2019) · Hematology · doi:10.1182/hematology.2019000365 · Cited by 9
“In addition, the relative abundance of gut microbes prior to ICI treatment has been correlated with ICI-related toxicity within the gut.(15,16) Notably, vancomycin-induced severe colitis in mice administered anti–CTLA-4 antibody therapy was ameliorated by the administration of a mixture of Bifidobacterium species, sug…”
BackgroundHamza, M., Wang, S., Liu, Y., Li, K., Zhu, M., & Chen, L. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128156 · Cited by 6
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 8
“[167] In colitis models constructed using both rats and mice, the administration of Parabacteroides goldsteinii substantially alleviated the common symptoms of colitis.”
Wang, R., Zhong, D., Jin, K., Tong, A., Li, L., Zheng, Y., Cui, J., Liu, X., Wang, Z., & Zhou, M. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100182 · Cited by 8
Hearn, J., Malik, G., Stukalin, I., Panaccione, R., Ingram, R. J. M., & Ma, C. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001847 · Cited by 6
“13,14 Case reports described the safety and ef fi cacy of FMT, including a recent 12-patient case series reporting induction of remission in 92% of cases of ICI colitis refractory to corticosteroids and a fi rst-line biologic.”
Dietary Fiber and Melanoma: Exploring Microbiome-Driven Immune Modulation
Turner, L. M., Sisk, C. K., & Yusuf, N. (2026) · Cancers · doi:10.3390/cancers18020203 · Cited by 6
“In combination therapy, similar results were found, where Bacteroides species were associated with lower colitis risk [75].”
Microbiota and immune-related adverse events in cancer immunotherapy
Schneider, S. M., Fan, C., Wang, Y., Jenq, R. R., & Watowich, S. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00921-3 · Cited by 8
“As described in the main text, the composition of the gut microbiome has been associated with irAEs, particularly immune checkpoint inhibitor (ICI) colitis 14–16, 55, 56 .”
Mechanisms underlying immune-related adverse events during checkpoint immunotherapy
Zhou, X., Chen, X., Han, L., & Liu, H. (2022) · Clinical Science · doi:10.1042/cs20210042 · Cited by 7
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
Ascierto, P. A., Agarwala, S. S., Blank, C. U., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03592-4 · Cited by 6
“In patients with metastatic melanoma treated with ipilimumab, increased Bacteroidetes phylum was correlated with less checkpoint-blockade-induced colitis, whereas Ruminococcus presence was associated with colitis [48].”
BackgroundNobre, J. G., Gaspar, I., & Costa, D. A. (2023) · Frontiers in Microbiomes · doi:10.3389/frmbi.2023.1217820 · Cited by 8
“Rikenellaceae _RC9 also has the ability to decrease colitis symptoms through anti-in fl ammatory mechanisms and CTLA-4 disruption by increasing the differentiation of regulatory T-cell (Dubin et al., 2016; An et al., 2021).”
Monson, K. R., Ferguson, R., Handzlik, J. E., Xiong, J., Dagayev, S., Morales, L. J., Chat, V., Bunis, A., Sreenivasaiah, C., Dolfi, S. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0900 · Cited by 9
Podder, V., Ranjan, T., Margolin, K. A., Maharaj, A., & Ahluwalia, M. S. (2024) · Cancers · doi:10.3390/cancers16233929 · Cited by 6
Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response
Chacon, J. A., Faizuddin, F., McKee, J. C., Sheikh, A., Vasquez, V. M., Gadad, S. S., Mayer, G., Siby, S., McCabe, M. M., & Dhandayuthapani, S. (2025) · Cancers · doi:10.3390/cancers17050813 · Cited by 8
“…employing tools such as dietary adjustments, probiotics, prebiotics, and FMT. Researchers are exploring these methods not only to boost the effectiveness of treatments but also to improve the quality of life for cancer patients by leveraging the gut’s profound influence on immune function [89,133].”
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma
Bonhomme‐Faivre, L., Guarino, V., & Misra, S. C. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221105572 · Cited by 7
Fedyanin, M. Y., Владимирович, С. А., Breder, V. V., Linkova, Y. N., Zinkina-Orikhan, A. V., Setkina, S. B., Фогт, С. Н., Chistyakov, V., & Kravtsova, N. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-2-360 · Cited by 6
Pasoto, S. G., Franco, A. S., Silva, C. A., & Bonfá, E. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2370327 · Cited by 7
“Study assessing intestinal microbiota in patients undergoing anti-CTLA-4 treatment demonstrated that a significant increase in the Bacteroidetes phylum reduced the likelihood of colitis [62].”
Das Mikrobiom – die unplanbare Größe zukünftiger Therapien
Beule, A. G. (2018) · Laryngo-Rhino-Otologie · doi:10.1055/s-0043-122301 · Cited by 12
“Finally, an immune-triggered colitis under CTLA4 therapy with Ipilimumab can be avoided by Bacteroides phlilym enhancement [187].”
BackgroundTesting Immune-Related Adverse Events in Cancer Immunotherapy
Farmer, J. R. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.07.012 · Cited by 6
Soni, T., Pandit, R. J., Blake, D. P., Joshi, C., & Joshi, M. N. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.08.017 · Cited by 6
Cancer immunotherapy and its renal effects
Mamlouk, O., & Abudayyeh, A. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319866837 · Cited by 6
Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
Parthymos, I., Liamis, G. L., Dounousi, E. C., Pentheroudakis, G. E., Mauri, D., Zarkavelis, G., & Florentin, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102979 · Cited by 6
Spain, L. A., Larkin, J., & Martín-Liberal, J. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1845-2 · Cited by 6
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
The Gut–Brain–Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities
Feng, R., Yang, Z., Zhou, Y., & Zhao, H. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01680-3 · Cited by 8
“…the presence of Fusobacterium and specific Firmicutes species has been correlated with a higher incidence of colitis following CTLA-4 inhibition, possibly mediated through ICOS-dependent expansion of CD4⁺ T cells and increased serum levels of sCD25 (Chaput et al. 2017; Dubin et al. 2016).”
Hobson, C. A., Vigué, L., Magnan, M., Chassaing, B., Naimi, S., Gachet, B., Claraz, P., Storme, T., Bonacorsi, S., Tenaillon, O., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.886447 · Cited by 5
“, 2018) or infectious anticancer-treatment-related side effects (Dubin et al., 2016; Montassier et al., 2016; Aarnoutse et al., 2019).”
BackgroundThe Intestinal Microbiota and Therapeutic Responses to Immunotherapy
Herrera, P. S., & van den Brink, M. R. M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-035210 · Cited by 6
Gault, A., Hogarth, L., Williams, K. C., Greystoke, A., Rajan, N., Speight, A., Lamb, C. A., Bridgewood, A., Brown-Schofield, L.-J., Rayner, F., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12468-3 · Cited by 5
Influence of gut microbiota on systemic immune responses and cancer immunotherapy
Murakonda, S. P., Balusu, S., Chava, H., Murakonda, A. B., Polneedi, R., Bodduluri, S., Gupta, S. C., & Challagundla, K. B. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.005 · Cited by 6
Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024
Jia, Z., Zhang, Y., Cao, L., Wang, J., & Liang, H. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2464379 · Cited by 7
The Role of the Intestinal Microbiome in the Immunotherapy of Colon Cancer
Хакимова, Г. Г., Tryakin, A. A., Заботина, Т. Н., Цуканов, А. С., Алиев, В. А., & Гуторов, С. Л. (2019) · Malignant tumours · doi:10.18027/2224-5057-2019-9-2-5-11 · Cited by 6
Zhang, J., Chen, X., Zou, J., Li, C., Kang, W., Guo, Y., Liu, S., Zhao, W., Mou, X., Huang, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02116-22 · Cited by 9
The Role of the Microbiome in Cancer Therapies
Chalif, J., Goldstein, N. E. S., Mehra, Y., Spakowicz, D. J., & Chambers, L. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.12.005 · Cited by 7
Gut Microbiome: The Third Musketeer in the Cancer-Immune System Cross-Talk
Sharma, P., Jain, T., Sethi, V., Iyer, S., & Dudeja, V. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000057 · Cited by 6
“Even the immune-related toxicity of ICIs have been associated with the gut microbiome composition, as bacteria from Bacteroidetes phylum were associated with lower rate of CTLA4 -induced colitis.([65]) The contrasting results with some studies”
ResultRivet, V., Quantin, X., Faillie, J., Lesage, C., Meunier, L., Faure, S., Hillaire‐Buys, D., Souder, C. L., Fabre, S., Assénat, E., et al. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.01.002 · Cited by 7
The microbiome and precision oncology: an emerging paradigm in anticancer therapy
Bhat, S. A., Kaur, R., Chauhan, A., & Pal, A. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2035313 · Cited by 8
“Furthermore, Dubin et al. corroborated the above results, reporting that the gavage feeding of Bacteroidetes (B. fragilis and B. cepacian) to mice rescued the non-responsiveness of the anti-CTLA4 monoclonal antibody ipilimumab (Dubin et al. 2016).”
BackgroundResultInfluentialThe interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy
Dehinsilu, J., Sergaki, C., Amos, G. C. A., Fontana, V., & Pirmohamed, M. (2023) · Frontiers in Microbiomes · doi:10.3389/frmbi.2023.1061193 · Cited by 6
“In pre-treatment faecal samples, increased representation of the Bacteroidetes phylum (including members of the Bacteriodaceae family) correlated with resistance to ipilimumab induced colitis in metastatic melanoma patients (Dubin et al., 2016).”
BackgroundInfluentialGut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy
Barroso‐Sousa, R., & Teles, L. T. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00346-y · Cited by 6
Kim, S. T., & Suarez-Almazor, M. E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1559731 · Cited by 6
Microbiome and Immunotherapy for Melanoma
Haddad, A., & Holder, A. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.010 · Cited by 5
Adhikari, N. P., Adhikari, S., & Rijal, K. R. (2024) · International Microbiology · doi:10.1007/s10123-024-00607-6 · Cited by 4
“Modularity affects the stability of a community by exposing biological processes, such as the common ecological functions among different groups of organisms within a module or similar habitat preferences (Dubin et al. 2016; Zhang et al. 2018; Hernandez et al. 2021).”
Qian, M., Ma, P., Zhao, Y., Jiang, H., Gao, L., Lin, G., Duan, D., & Guo, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662333 · Cited by 6
“This inconsistency may stem from variations in the baseline intestinal fl ora among patients (28, 29).”
Unveiling the interplay between gut and skin microbiomes and their influence on skin cancer
Charbel, N., Masri, A., Rammal, F., Aramouni, K., Jabbour, K., Hodroj, M. H., Rizkallah, J., Kabbara, F., & Kreidieh, F. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00270-24 · Cited by 6
“For example, an overabundance of the Bacteroides genus in the microbiome of patients with melanoma has been associated with a reduced risk of colitis during immunotherapy but a lower response rate to treatment (118).”
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4
Reddy, N., Lau, K., Naman, J., Lu, K. L., McGillivary, E., Salmasi, A., Liss, M. A., & Stewart, T. F. (2026) · OncoImmunology · doi:10.1080/2162402x.2025.2611458 · Cited by 4
Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity
Jiménez-Andrade, Y., Flesher, J. L., & Park, J. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.002 · Cited by 4
Hypophysitis Associated with Immune Checkpoint Inhibitors
Corsello, A., Paragliola, R. M., Torino, F., & Salvatori, R. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.06.009 · Cited by 4
Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption
Amin, R. N., Thomas, A. S., & Wang, Y. (2022) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2022.0490 · Cited by 4
Gastrointestinal Side Effects of Anticancer Therapy
Uranga, J. A., Nurgali, K., & Abalo, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_343-1 · Cited by 5
Patel, S. H., Becker, E., Ploix, C. C., Steiner, G., Šćepanović, P., Fueth, M., Mudry, M. C. D. V., Eichinger‐Chapelon, A., Marrer‐Berger, E., & Claesson, M. J. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300103 · Cited by 5
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Treatment of immune checkpoint inhibitor-related colitis: a narrative review
Wang, S., & Wang, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-2150 · Cited by 5
“Recent studies have shown that certain bacteria are associated with the onset and severity of ICIC (97,98).”
Influence of high-fiber diet on ipilimumab-induced gastrointestinal toxicity in metastatic melanoma
Majenka, P., Hoffmann, M., Strobel, S., Rötzer, I., Enk, A. H., & Hassel, J. C. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.026 · Cited by 5
Kim, S., Lahu, G., Vakilynejad, M., Soldatos, T. G., Jackson, D., Lesko, L. J., & Trame, M. N. (2022) · Clinical and Translational Science · doi:10.1111/cts.13254 · Cited by 4
Circulating biomarkers of response to immunotherapy and immune-related adverse events
Garrison, Z. R., Hornick, N. I., Cheng, J. B., & Kulkarni, R. P. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2130688 · Cited by 5
Microbiota Manipulation as an Emerging Concept in Cancer Therapy
Spalinger, M. R., & Scharl, M. M. (2023) · Visceral Medicine · doi:10.1159/000534810 · Cited by 4
“It is known that the occurrence and severity of ICI-induced colitis depends on the patient ’ s microbial composition [42] and FMT or supplementation of speci fi c bacterial strains might reduce this complication drastically [43].”
BackgroundStahel, R. A., Lacombe, D., Cardoso, F., Casali, P. G., Negrouk, A., Marais, R., Hiltbrunner, A., Vyas, M., Varoqueaux, N., Frohn, C., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000628 · Cited by 6
Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer
Zengin, Z. B., Salgia, N., Chehrazi‐Raffle, A., Meza, L., Malhotra, J., & Pal, S. K. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000473 · Cited by 5
“Gut microbiome composition has also been explored as a possible modulator of irAEs; the Bacteroidetes phylum has been associated with a reduced rate of ICI-induced colitis.(13) The toxicities associated with CTLA-4 and/or PD-1/PD-L1 inhibitors differ in incidence.”
BackgroundThe progress on the relationship between gut microbiota and immune checkpoint blockade in tumors
Jiang, H., Ye, Y., Wang, M., Sun, X., Sun, T., Chen, Y., Li, P., Zhang, M., & Wang, T. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2212526 · Cited by 5
“Another study reported that antibiotic use was associated with poorer prognosis in tumor-bearing mice and patients with metastatic colon and non-small cell lung cancer treated with anti-PD-1 and anti-CTLA-4 (Dubin et al., 2016).”
Microbiota predicts side-effects of immunotherapy
Bordon, Y. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.22 · Cited by 4
The double edge of cancer immunotherapy
(2017) · Nature Medicine · doi:10.1038/nm.4286 · Cited by 4
Zhao, B., Zhou, B., Li, Q., Su, C., Ma, J., & Yang, L. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.70006 · Cited by 3
GAUDIO, A. D., Lopetuso, L. R., Pavese, V., Palesandro, E., Campisi, I., Tucci, M., & Scaldaferri, F. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251358174 · Cited by 3
“37 Regarding the upper digestive tract, nausea, gas-tritis, duodenitis, and oesophagitis have been observed.”
Antohi, A. L., Gheorghiță, A. D., Andronic, O., Pîrcălăbioru, G. G., & Treteanu, A. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062538 · Cited by 6
Han, W., Li, Q., & Yuan, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802676 · Cited by 4
“A key premise underlying these efforts is that microbiome engineering may help broaden the therapeutic window of checkpoint blockade by jointly shaping antitumor ef fi cacy and in fl ammatory toxicity (16).”
Huang, R., Yao, Y., Tong, X., Wang, L., Qian, W., Lu, J., Zhang, W., Liu, Y., Wang, S., Xian, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00135-23 · Cited by 3
“For instance, bacteroidetes phylum might decreased the risk of encountering ICI-induced colitis (90).”
BackgroundEfficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review
Sang, Y., Zheng, K., Zhao, Y., Liu, Y., Zhu, S., Xie, X., Shang, L., Liu, J., & Li, L. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-316 · Cited by 4
“In previous melanoma studies, researchers found that the abundance and proportion of specific microbes (70) and the metabolic derivatives of certain microbes (71) were associated with the occurrence and/or severity of pathogenesis of irAEs.”
Update on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management
Wang, D., Zhao, Y., Zeng, Y., Hu, L., & Xu, C. S. (2024) · Malignancy Spectrum · doi:10.1002/msp2.50 · Cited by 3
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy
Braun, L. M., Lu, Y., & Zeiser, R. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.07.005 · Cited by 8
Innovation and Advances in Precision Medicine in Head and Neck Cancer
Watson, G. A., Taylor, K., & Siu, L. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-63234-2_24 · Cited by 3
Endoscopic and histopathologic features of Anti‐PD‐1‐related collagenous colitis
Kikuchi, H., Sakuraba, H., Akemoto, Y., Hosoi, K., Murai, Y., Hoshi, K., Fukutoku, Y., Asari, T., Sawada, Y., Hasui, K., et al. (2022) · DEN Open · doi:10.1002/deo2.92 · Cited by 3
Basic cancer immunology for radiation oncologists
Sia, J., Neeson, P. J., & Haynes, N. M. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13406 · Cited by 4
The interplay between anticancer challenges and the microbial communities from the gut
Hobson, C. A., Bonacorsi, S., Baruchel, A., Tenaillon, O., & Birgy, A. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04435-2 · Cited by 3
“1 3 therapies [16], or even the infectious anticancer-treatment related side effects [4, 17, 18].”
BackgroundImmunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
España, S., Sun, C., Solé-Blanch, C., Boada, A., Martínez‐Cardús, A., & Manzano, J. L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030823 · Cited by 4
“A study of 34 melanoma patients treated with anti-CTLA4 (ipilimumab) with some specific microbes from the Bacteroidetes phylum were associated with a reduced risk of colitis [68].”
Kashyap, S., & Das, A. (2023) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2023.02054 · Cited by 5
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Plazas, J. G., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10250/2024 · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.10.003 · Cited by 4
Hirata, Y., Tanaka, Y., Yokota, H., Ohno, H., Nishida, K., Shimizu, H., Mizuta, N., Nakazawa, K., Koshiba, R., Kakimoto, K., et al. (2024) · Gut Pathogens · doi:10.1186/s13099-024-00630-y · Cited by 3
“For instance, the abundance of microbes such as Bacteroidetes and Bifidobacterium has been associated with a reduced risk of gastrointestinal irAEs [6], whereas patients who developed gastrointestinal irAEs were reported to have an abundance of Fae-calibacterium and Firmicutes prior to ICI…”
BackgroundThe role of the microbiome in head and neck squamous cell cancers
Şahin, T. K., & Sönmezer, M. Ç. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-024-08966-6 · Cited by 4
“In their research on melanoma patients being treated with checkpoint inhibitors, Dubin and colleagues observed that those with a higher concentration of the Bac - teroidetes phylum in their intestines were less prone to develop immune checkpoint inhibitor-induced colitis [109 ].”
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
Festino, L., & Ascierto, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_33 · Cited by 4
Gastrointestinal Toxicity of Immunotherapy
Špaček, J. (2020) · Klinicka onkologie · doi:10.14735/amko202023 · Cited by 3
“V prospektivní studii s 34 pacienty, u nichž bylo analyzováno složení střevního mikrobio mu před zahájením imunoterapie, byla zjištěna zvýšená přítomnost bakterií kmene Bacteroides u pacientů, u kterých se při léčbě ipilimumabem neobjevila autoimunitní enterokolitida [7].”
Targeting Gut Microbiota in Colorectal Cancer
Wong, S. H. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_16 · Cited by 3
Gut Microbiota Impacts on the Efficacy of Anticancer Treatment of Colorectal Cancer
Hong, J., & Fang, J. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_15 · Cited by 3
Belcaid, L., Garaud, S., Kerger, J. N., Sideris, S., & Aspeslagh, S. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1664051 · Cited by 3
Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy
Welsh, S. J., & Corrie, P. G. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3497 · Cited by 3
“Similarly, preliminary studies suggest the microbiome (discussed in more detail below) may influence risk of irAEs, particularly colitis (46).”
BackgroundIwamoto, T., Nozaki, Y., Tsuji, S., Hukusima, H., Yamauchi, R., Nakanishi, R., Nagahama, S., Sunaga, K., Yamaoka, S., Suda, T., et al. (2020) · Kanzo · doi:10.2957/kanzo.61.572 · Cited by 3
Zaretsky, A. R., Демидов, Л. В., & Самойленко, И. В. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-9-48-63 · Cited by 4
The Microbiome-TIME Axis: A Host of Possibilities
Ross, T. J., & Zhang, J. (2023) · Microorganisms · doi:10.3390/microorganisms11020288 · Cited by 3
“[93] Bacteriodes Lowered risk of anti-CTLA-4 treatment-associated colitis”
Background
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.